National Institutes of Health (NIH)
Bethesda
MD
United States
285 articles with National Institutes of Health (NIH)
-
Known as the Reproducibility Project: Cancer Biology, it spent eight years replicating experiments from high-impact cancer biology papers published between 2010 and 2012.
-
ATCC Announces Award from National Institute of Allergy and Infectious Diseases (NIAID) to Develop Research Capabilities in Infectious, Immunologic and Allergic Diseases
11/23/2021
ATCC, the world’s premier biological materials management and standards organization, announced that it has been awarded a seven-year, Indefinite Delivery/Indefinite Quantity contract with a ceiling value of $545 million by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
-
Boston Children's Hospital to co-lead a 25-center NIH-funded study of brain development from birth to age 10
11/17/2021
Study will investigate how a broad range of exposures affect brain and child development.
-
Delpor Advances Pipeline to Include Spasticity Maintenance Therapy with $2.5 Million NIH Grant for Tizanidine Implant
11/16/2021
Delpor, Inc., a clinical stage biopharmaceutical company that utilizes innovative technologies to develop once-yearly therapies for chronic conditions, announced an NIH grant award of $2.5 million for the further advancement of the company’s tizanidine implant product for moderate-severe spasticity.
-
Researchers have published a study of a woman being called the "Esperanza patient," one of what researchers call "elite controllers," who seem to eradicate HIV naturally.
-
HSS Scientist Awarded Two NIH Grants Totaling $6 Million
11/11/2021
A scientist at Hospital for Special Surgery, Chitra Dahia, PhD, has received two National Institutes of Health grants totaling $6 million for translational research aimed at understanding the root cause of disc degeneration and chronic back pain in order to develop treatment options that do not rely on addictive pain-relieving medications.
-
Texas Based 4E Therapeutics Awarded National Institutes of Health Research Grant to Develop Non-Opioid Treatment for Pain to End Addiction
11/10/2021
4E Therapeutics, Inc. announced that it has been awarded a $5.5 million Phase 2 National Institutes of Health (NIH) Small Business Innovation Research (SBIR) UG3 grant as part of the NIH Helping to End Addiction Long-Term (HEAL) Initiative.
-
Virpax Advances Envelta™ Development with NCATS Under CRADA Agreement
11/10/2021
Virpax® Pharmaceuticals, Inc. announced that the National Center for Advancing Translational Sciences at the National Institutes of Health has awarded research and development contracts to support Good Manufacturing Practices production of drug substance and drug product.
-
Public Citizen urged NIH director Dr. Francis Collins to clarify the NIH's role in Moderna's vaccine publicly and explain what he plans to ensure that federal scientists are credited for their work.
-
DNA Script to Develop Next Generation of Enzymatic DNA Synthesis Printers with $2.2 Million Grant Award from the National Human Genome Research Institute of the NIH
11/9/2021
DNA Script, a leader in benchtop enzymatic DNA synthesis, announced that the company has received a $2.2 million grant award from the National Human Genome Research Institute of the National Institutes of Health to support the ongoing development of next generation printers to enzymatically print synthetic DNA and RNA as a follow-on to their recently launched SYNTAX System.
-
The National Institutes of Health has removed a notice aimed at encouraging grant proposals from minority scientists from three separate institutes.
-
Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for Treatment of B-cell non-Hodgkin Lymphomas
11/1/2021
Mustang Bio, Inc. today announced that the company has been awarded a grant of approximately $2 million from the National Cancer Institute of the National Institutes of Health (“NIH”).
-
The Lundquist Institute Receives $3 Million From NIH To Expand Male Contraception Study
10/27/2021
The Lundquist Institute announced that its Male Contraceptive Efficacy Trial has received an additional $3 million from the National Institutes of Health to expand its work and recruit 120+ more couples.
-
Albert Einstein College of Medicine Receives $4 Million NIH Grant To Support Diabetes Prevention and Management Research
10/20/2021
Albert Einstein College of Medicine has received a five-year, $4 million grant from the National Institutes of Health to support the New York Regional Center for Diabetes Translation Research.
-
Detect™ Selected by NIH to Scale Manufacturing of PCR-Quality Rapid At-Home Covid-19 Test
10/14/2021
Detect™, Inc., a Connecticut-based health technology company, announced that the National Institutes of Health has selected the Detect™ Covid-19 Test to receive funding from the highly competitive Rapid Acceleration of Diagnostics Initiative.
-
The NIH revealed that bumetanide, a drug typically used as a diuretic, maybe a potential treatment for those genetically at risk for Alzheimer's. Know more about it here.
-
Acting FDA Commissioner Janet Woodcock’s days as interim head of the agency are numbered due to federal regulations. Speculations are rampant on a number of potential choices.
-
After serving three presidential administrations, Dr. Francis S. Collins is stepping down as director of the National Institutes of Health at the end of the year.
-
Investing in Future Scientists, Feinstein Institutes Gets $1.5M NIH Grant to Develop Training Program
10/1/2021
Doubling down on efforts to prepare highly qualified young scientists for a career in immune disease-focused medical research, The Feinstein Institutes for Medical Research, the science arm of Northwell Health, has been awarded a multi-year National Institutes for Health grant totaling $1.5 million.
-
NRx Pharmaceuticals Announces Second Favorable Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
9/29/2021
NRx Pharmaceuticals, a clinical stage, biopharmaceutical company provided a safety update on ZYESAMI™ which is being tested in the ACTIV-3b Critical Care Phase 3 study sponsored by the National Institutes of Health.